X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Panacea Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs PANACEA BIOTECH - Comparison Results

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA PANACEA BIOTECH AJANTA PHARMA/
PANACEA BIOTECH
 
P/E (TTM) x 24.9 171.2 14.6% View Chart
P/BV x 10.3 3.8 270.3% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 AJANTA PHARMA   PANACEA BIOTECH
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
PANACEA BIOTECH
Mar-14
AJANTA PHARMA/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs1,720149 1,156.7%   
Low Rs1,10382 1,340.2%   
Sales per share (Unadj.) Rs194.684.1 231.3%  
Earnings per share (Unadj.) Rs45.2-18.3 -247.0%  
Cash flow per share (Unadj.) Rs50.3-6.7 -750.8%  
Dividends per share (Unadj.) Rs8.000-  
Dividend yield (eoy) %0.60-  
Book value per share (Unadj.) Rs132.083.7 157.7%  
Shares outstanding (eoy) m88.7761.25 144.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.31.4 528.4%   
Avg P/E ratio x31.2-6.3 -494.8%  
P/CF ratio (eoy) x28.1-17.2 -162.8%  
Price / Book Value ratio x10.71.4 774.8%  
Dividend payout %17.70-   
Avg Mkt Cap Rs m125,2997,074 1,771.2%   
No. of employees `000NA2.8 0.0%   
Total wages/salary Rs m2,5701,449 177.3%   
Avg. sales/employee Rs ThNM1,874.1-  
Avg. wages/employee Rs ThNM527.0-  
Avg. net profit/employee Rs ThNM-407.7-  
INCOME DATA
Net Sales Rs m17,2755,154 335.2%  
Other income Rs m166100 166.6%   
Total revenues Rs m17,4425,254 332.0%   
Gross profit Rs m5,807-766 -757.8%  
Depreciation Rs m451711 63.4%   
Interest Rs m491,503 3.3%   
Profit before tax Rs m5,474-2,881 -190.0%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m0-6 0.0%   
Extraordinary Inc (Exp) Rs m01,771 0.0%   
Tax Rs m1,46017 8,689.9%   
Profit after tax Rs m4,014-1,121 -358.0%  
Gross profit margin %33.6-14.9 -226.1%  
Effective tax rate %26.7-0.6 -4,572.7%   
Net profit margin %23.2-21.8 -106.8%  
BALANCE SHEET DATA
Current assets Rs m7,6393,810 200.5%   
Current liabilities Rs m2,7158,365 32.5%   
Net working cap to sales %28.5-88.4 -32.2%  
Current ratio x2.80.5 617.8%  
Inventory Days Days43156 27.8%  
Debtors Days Days7967 117.0%  
Net fixed assets Rs m6,91414,480 47.7%   
Share capital Rs m17761 288.6%   
"Free" reserves Rs m11,442903 1,266.9%   
Net worth Rs m11,7215,127 228.6%   
Long term debt Rs m1495,832 2.5%   
Total assets Rs m14,81419,433 76.2%  
Interest coverage x112.9-0.9 -12,323.3%   
Debt to equity ratio x01.1 1.1%  
Sales to assets ratio x1.20.3 439.7%   
Return on assets %27.42.0 1,396.3%  
Return on equity %34.2-21.9 -156.6%  
Return on capital %46.53.6 1,279.6%  
Exports to sales %55.124.5 224.9%   
Imports to sales %6.010.2 59.0%   
Exports (fob) Rs m9,5271,264 753.8%   
Imports (cif) Rs m1,038525 197.7%   
Fx inflow Rs m10,4221,539 677.1%   
Fx outflow Rs m1,678942 178.2%   
Net fx Rs m8,744597 1,464.1%   
CASH FLOW
From Operations Rs m3,264599 544.7%  
From Investments Rs m-2,093-438 477.9%  
From Financial Activity Rs m-1,186-303 391.8%  
Net Cashflow Rs m-15-141 10.5%  

Share Holding

Indian Promoters % 73.8 74.5 99.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 0.6 258.3%  
FIIs % 7.6 1.3 584.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 23.6 72.0%  
Shareholders   20,968 10,259 204.4%  
Pledged promoter(s) holding % 4.4 35.1 12.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   PFIZER  GSK PHARMA  PLETHICO PHARMA  WYETH LTD  ABBOTT INDIA  

Compare AJANTA PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Feb 23, 2018 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 8-QTR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS